Patents by Inventor Wolfgang Pfleiderer

Wolfgang Pfleiderer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8445734
    Abstract: The present invention discloses novel and improved nucleosidic and nucleotidic compounds that are useful in the light-directed synthesis of oligonucleotides, as well as, methods and reagents for their preparation. These compounds are characterized by novel photolabile protective groups that are attached to either the 5?- or the 3?-hydroxyl group of a nucleoside moiety. The photolabile protective group is comprised of a 2-(2-nitrophenyl)-ethyoxycarbonyl skeleton with at least one substituent on the aromatic ring that is either an aryl, an aroyl, a heteroaryl or an alkoxycarbonyl group. The present invention includes the use of the aforementioned compounds in light-directed oligonucleotide synthesis, the respective assembly of nucleic acid microarrays and their application.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: May 21, 2013
    Assignee: NIGU Chemie GmbH
    Inventors: Sigrid Buehler, Markus Ott, Wolfgang Pfleiderer
  • Publication number: 20120251495
    Abstract: Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as hepatitis B virus infection based upon the administration of calcium pterin. In one embodiment is a method of treating cancer comprising administration of dipterinyl calcium pentahydrate (DCP). In another embodiment is a method of treating hepatitis B virus infection comprising administration of dipterinyl calcium pentahydrate (DCP).
    Type: Application
    Filed: January 16, 2009
    Publication date: October 4, 2012
    Inventors: Phillip Moheno, Wolfgang Pfleiderer, Antonio DiPasquale, Arnold Rheingold, Dietmar Fuchs
  • Publication number: 20100292458
    Abstract: The present invention discloses novel and improved nucleosidic and nucleotidic compounds that are useful in the light-directed synthesis of oligonucleotides, as well as, methods and reagents for their preparation. These compounds are characterized by novel photolabile protective groups that are attached to either the 5?- or the 3?-hydroxyl group of a nucleoside moiety. The photolabile protective group is comprised of a 2-(2-nitrophenyl)-ethyoxycarbonyl skeleton with at least one substituent on the aromatic ring that is either an aryl, an aroyl, a heteroaryl or an alkoxycarbonyl group. The present invention includes the use of the aforementioned compounds in light-directed oligonucleotide synthesis, the respective assembly of nucleic acid microarrays and their application.
    Type: Application
    Filed: June 2, 2010
    Publication date: November 18, 2010
    Applicant: NIGU Chemie GmbH
    Inventors: Sigrid BÜHLER, Markus Ott, Wolfgang Pfleiderer
  • Patent number: 7759513
    Abstract: The present invention discloses novel and improved nucleosidic and nucleotidic compounds that are useful in the light-directed synthesis of oligonucleotides, as well as, methods and reagents for their preparation. These compounds are characterized by novel photolabile protective groups that are attached to either the 5?- or the 3?-hydroxyl group of a nucleoside moiety. The photolabile protective group is comprised of a 2-(2-nitrophenyl)-ethyoxycarbonyl skeleton with at least one substituent on the aromatic ring that is either an aryl, an aroyl, a heteroaryl or an alkoxycarbonyl group. The present invention includes the use of the aforementioned compounds in light-directed oligonucleotide synthesis, the respective assembly of nucleic acid microarrays and their application.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: July 20, 2010
    Assignee: NIGU Chemie GmbH
    Inventors: Sigrid Bühler, Markus Ott, Wolfgang Pfleiderer
  • Publication number: 20100105692
    Abstract: Provided herein is dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. Also provided herein is the compound dipterinyl calcium pentahydrate (DCP) or an analog or polymorph thereof.
    Type: Application
    Filed: December 21, 2009
    Publication date: April 29, 2010
    Inventors: Phillip Moheno, Wolfgang Pfleiderer
  • Patent number: 7662820
    Abstract: Provided herein is dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. Also provided herein is the compound dipterinyl calcium pentahydrate (DCP) or an analog or polymorph thereof.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 16, 2010
    Assignee: SanRX Pharmaceuticals, Inc.
    Inventors: Phillip Moheno, Wolfgang Pfleiderer
  • Publication number: 20090264415
    Abstract: This invention relates to substituted pyrido(3,2-d)pyrimidine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These derivatives are also useful in preventing or treating cardiovascular disorders, disorders of the central nervous system, TNF-? related disorders, viral diseases (including hepatitis C), erectile dysfunction and cell proliferative disorders.
    Type: Application
    Filed: June 20, 2008
    Publication date: October 22, 2009
    Inventors: Steven De Jonghe, Eduard Dolusic, Ling-Jie Gao, Piet Herdewijn, Wolfgang Pfleiderer
  • Publication number: 20080166355
    Abstract: Provided herein is dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. Also provided herein is the compound dipterinyl calcium pentahydrate (DCP) or an analog or polymorph thereof.
    Type: Application
    Filed: October 30, 2007
    Publication date: July 10, 2008
    Applicant: SanRx Pharmaceuticals, Inc.
    Inventors: Phillip Moheno, Wolfgang Pfleiderer
  • Publication number: 20080004285
    Abstract: This invention relates to substituted pyrido(3,2-d)pyrimidine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These derivatives are also useful in preventing or treating cardiovascular disorders, disorders of the central nervous system, TNF-? related disorders, viral diseases (including hepatitis C), erectile dysfunction and cell proliferative disorders.
    Type: Application
    Filed: June 29, 2007
    Publication date: January 3, 2008
    Inventors: Steven De Jonghe, Eduard Dolusic, Ling-Jie Gao, Piet Andre Herdewijn, Wolfgang Pfleiderer
  • Publication number: 20070043000
    Abstract: Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceutically acceptable salts thereof, are useful as biologically active ingredients in preparing pharmaceutical compositions especially for the treatment or prevention of a CNS disorder, a cell proliferative disorder, a viral infection, an immune or auto-immune disorder or a transplant rejection. Combinations of the pteridine derivatives of the invention with an immunosuppressant or immunomodulator drug, an antineoplastic drug or an antiviral agent, providing potential synergistic effects, are also disclosed.
    Type: Application
    Filed: May 21, 2004
    Publication date: February 22, 2007
    Inventors: Mark Waer, Piet Andre Herdewijn, Wolfgang Pfleiderer
  • Publication number: 20060287314
    Abstract: This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydro-derivatives and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These compounds are also useful in preventing or treating cardiovascular disorders, allergic conditions, disorders of the central nervous system and cell proliferative disorders.
    Type: Application
    Filed: August 27, 2004
    Publication date: December 21, 2006
    Inventors: Mark Waer, Wolfgang Pfleiderer, Piet Andre Herdewijn, Arnaud Marchand, Steven Jonghe
  • Publication number: 20060189620
    Abstract: This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydroderivatives and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These compounds are also useful in preventing or treating cardiovascular disorders, allergic conditions, disorders of the central nervous system and cell proliferative disorders.
    Type: Application
    Filed: January 18, 2006
    Publication date: August 24, 2006
    Inventors: Mark Jozef Waer, Piet Andre Herdewijn, Wolfgang Pfleiderer
  • Patent number: 6858612
    Abstract: The present invention relates to the use of pteridine derivatives of the formula I in which X is O or NH and R4, for example, is hydrogen, phenyl or the radical R4a—CH2— and R4a, for example, is hydrogen, (C1-C4)-alkylmercapto, the radical —NR11R12 or the radical —OR13, and in which R1, R2, R3, R5, R6, R7, R11, R12 and R13 have the meanings given in claim 1, which are nitric oxide synthase inhibitors, for the treatment of diseases which are caused by an increased nitric oxide level.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: February 22, 2005
    Assignee: Vasopharm Buitech GmbH
    Inventors: Wolfgang Pfleiderer, Harald Schmidt, Rainer Henning
  • Patent number: 6844343
    Abstract: Compounds of formula (I), where preferably: A=a bridge of partial formula (II) or (III), R1 and R2=independently (substituted) alkyl, aryl or aralkyl, or together form a heterocycle, R3=H, —CO-Alkyl, or —CO-Aryl, R4=Aryl, —CO—O-Aryl or —CO-Aryl and R5=H, are potent inhibitors of NO-synthase and are suitable as pharmaceutical agents of prophylaxis and treatment of disease states associates with a disturbed NO metabolism.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: January 18, 2005
    Assignee: Vasopharm Biotech GmbH
    Inventors: Wolfgang Pfleiderer, Harald Schmidt, Lothar Fröhlich, Peter Kotsonis, Shahriyar Taghavi-Moghadam
  • Publication number: 20040203036
    Abstract: The present invention relates to a process for the preparation of polynucleotides, whereby under suitable usual conditions the free 5′-hydroxy group, whose terminal 3′-hydroxy group contains a usual protecting group, is reacted with a hydroxy group, derivatized in a previous reaction step to a phosphite amidoester, phosphpotriester or phosphonic acid ester, whereby said hydroxy group is a 3′-hydroxy function of a free or solid phase bound polynucleotide, or a solid phase bound hydroxy function.
    Type: Application
    Filed: January 9, 2004
    Publication date: October 14, 2004
    Inventors: Klaus-Peter Stengele, Wolfgang Pfleiderer
  • Publication number: 20040175741
    Abstract: The present invention discloses novel and improved nucleosidic and nucleotidic compounds that are useful in the light-directed synthesis of oligonucleotides, as well as, methods and reagents for their preparation. These compounds are characterized by novel photolabile protective groups that are attached to either the 5′- or the 3′-hydroxyl group of a nucleoside moiety. The photolabile protective group is comprised of a 2-(2-nitrophenyl)-ethyoxycarbonyl skeleton with at least one substituent on the aromatic ring that is either an aryl, an aroyl, a heteroaryl or an alkoxycarbonyl group. The present invention includes the use of the aforementioned compounds in light-directed oligonucleotide synthesis, the respective assembly of nucleic acid microarrays and their application.
    Type: Application
    Filed: January 26, 2004
    Publication date: September 9, 2004
    Applicant: NIGU Chemie GmbH
    Inventors: Sigrid Buhler, Markus Ott, Wolfgang Pfleiderer
  • Patent number: 6750335
    Abstract: The invention relates to nucleoside derivatives with photolabile protecting groups of general formula (I) wherein R1 is H, F, Cl, Br, I, or NO2; R2 is H or CN, provided that R1 and R2 are not simultaneously H; R3 is H, 1-4 C alkyl, or phenyl; R4 is H or a conventional functional group for the synthesis of oligonuleotides; R5 is H, OH, halogen or XR6, where X=O or S, and R6 is a conventional nucleotide protecting group; and B is adenine, cytosine, guanine, thymine, uracil, 2,6-diaminopurin-9-yl, hypoxanthin-9-yl, 5-methylcytosin-1-yl, 5-amino-4-imidazolcarboxamid-1-yl or 5-amino-4-imidazolcarboxamid-3-yl, where, if B is adenine, cytosine or guanine the primary amine functionality, optionally, carries a permanent protecting group. Furthermore, these derivatives may be used for the light-controlled synthesis of oligonucleotides on a DNA chip.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: June 15, 2004
    Assignee: Nigu Chemie GmbH
    Inventors: Wolfgang Pfleiderer, Sigrid Bühler, Heiner Giegrich
  • Patent number: 6716971
    Abstract: The invention provides pteridine nucleotides of formula (I) which are highly fluorescent and which can be used in the chemical synthesis of fluorescent oligonucleotide. The invention further provides for fluorescent oligonucleotide comprising one or more pteridine nucleotides. In addition the invention provides for pteridine nucleotide triphosphates which may be used as the constituent monomers in DNA amplification procedures. The pteridine nucleotides are more stable and possess higher quantum yields than structurally similar pteridine nucleotides.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: April 6, 2004
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Mary E. Hawkins, Wolfgang Pfleiderer, Frank Balis
  • Publication number: 20020146737
    Abstract: The invention relates to nucleoside derivatives with photolabile protecting groups of general formula (I), where R1=H, F, Cl, Br, I, NO2; R2=H, CN, where R1 and R2 are not simultaneously H; R3=H, 1-4 C alkyl, phenyl; R4=H or a conventional functional group for the synthesis of oligonucleotides; R5=H, OH, halogen or XR6, where X=O or S and R6=a conventional nucleotide protecting group; B=adenine, cytosine, guanine, thymine, uracil, 2,6-diaminopurin-9-yl, hypoxanthin-9-yl, 5-methylcytosin-1-yl, 5-amino-4-imidazolcarboxamid-1-yl or 5-amino-4-imidazolcarboxamid-3-yl, where, if B=adenine, cytosine or guanine the primary amine functionality, optionally, carries a permanent protecting group. Furthermore, these derivatives may be used for the light-controlled synthesis of oligonucleotides on a DNA chip.
    Type: Application
    Filed: March 29, 2002
    Publication date: October 10, 2002
    Inventors: Wolfgang Pfleiderer, Sigrid Buhler, Heiner Giegrich
  • Patent number: 6362171
    Abstract: Antiviral compounds and the water-soluble salts thereof have formula (I), wherein n is from 1 to 8; R1 is selected from the group consisting of (a), wherein m is zero, 1, 2 or 3; and (b), wherein q is from 1 to 20; R2 is independently selected from the group consisting of oxygen and sulfur; R3 is independently selected from the group consisting of hydrogen and hydroxyl; and R4 is selected from the group consisting of hydrogen, hydroxyl and (b); R5 is selected from the group consisting of hydroxyl and (b); R6 is selected from the group consisting of (c), (d) et (e), wherein x is from 1 to 20; provided that one of R1, R4 and R5 is (b) wherein R6 is defined as above; or water soluble salt thereof.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: March 26, 2002
    Assignee: Temple University-of the Commonwealth System of Higher Education
    Inventors: Robert J. Suhadolnik, Wolfgang Pfleiderer